RSS-Feed abonnieren
DOI: 10.1055/s-0039-1677792
Are Subchondral Intraosseous Injections Effective and Safe for the Treatment of Knee Osteoarthritis? A Systematic Review
Publikationsverlauf
11. Oktober 2018
16. Dezember 2018
Publikationsdatum:
06. Februar 2019 (online)
![](https://www.thieme-connect.de/media/jks/201911/lookinside/thumbnails/10-1055-s-0039-1677792_18oct0032ssa-1.jpg)
Abstract
Knee osteoarthritis (OA) is a highly prevalent disease and treatment options for early stages of OA are needed. Intraosseous injections of bone substitute and biologic materials have been proposed to expand the therapeutic arsenal by potentially halting OA progression and delaying the need for knee arthroplasty in patients with early/moderate-stage disease. Therefore, the goal of this study was assessed the efficacy and safety of subchondral intraosseous injection for the treatment of knee OA. A systematic review was performed on PubMed-Medline, and the Cochrane Database of systematic reviews. English and Spanish retrospective and prospective studies assessing the results of subchondral intraosseous injection of bone substitute materials and/or biologicals in human patients with knee OA, with a minimum of 6 months of follow-up were collected. A total of 1,081 potential articles were identified through our search. Six studies were included with a total of 163 patients. The mean follow-up was 18 months (range: 6–24 months). Patient reported outcomes measures (PROMs), complications, and conversion to total knee arthroplasty (TKA) were collected. All six studies showed PROMs improvement relative to baseline. Overall, the five studies reporting visual-analog scale (VAS) pain outcomes improved from a baseline mean score of 6.68 to 2.74. Also, knee injury and osteoarthritis score (KOOS), Tegner-Lysholm, and/or international knee documentation committee (IKDC) scores rose compared with baseline scores in all studies. Overall, 2.5% (4/163) of patients had a complication attributed to study-related treatment. Most patients (81%, 86/106) remained TKA-free at a 1-year follow-up. Subchondral intraosseous injections of bone substitute materials and platelet-rich plasma (PRP) suggest (1) improved PROMs of pain and functional status, (2) low complication rate, and (3) relatively low rates of conversion to TKA. However, the current studies investigating these treatments exhibited high degree of heterogeneity in both measurement of outcomes and delivery of treatment, with a high risk of bias. This procedure should not be utilized in advanced knee OA. In light of the limitations of the current literature, advising in favor or against this therapy for early to moderate knee OA is challenging.
-
References
- 1 Nielsen FK, Egund N, Jørgensen A, Jurik AG. Risk factors for joint replacement in knee osteoarthritis; a 15-year follow-up study. BMC Musculoskelet Disord 2017; 18 (01) 510
- 2 Nguyen U-SDT, Zhang Y, Zhu Y, Niu J, Zhang B, Felson DT. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med 2011; 155 (11) 725-732
- 3 Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin North Am 2013; 39 (01) 1-19
- 4 Carr AJ, Robertsson O, Graves S. , et al. Knee replacement. Lancet 2012; 379 (9823): 1331-1340
- 5 Glyn-Jones S, Palmer AJR, Agricola R. , et al. Osteoarthritis. Lancet 2015; 386 (9991): 376-387
- 6 Chatterjee D, McGee A, Strauss E, Youm T, Jazrawi L. Subchondral calcium phosphate is ineffective for bone marrow edema lesions in adults with advanced osteoarthritis. Clin Orthop Relat Res 2015; 473 (07) 2334-2342
- 7 Mantripragada VP, Piuzzi NS, Zachos T, Obuchowski NA, Muschler GF, Midura RJ. High occurrence of osteoarthritic histopathological features unaccounted for by traditional scoring systems in lateral femoral condyles from total knee arthroplasty patients with varus alignment. Acta Orthop 2018; 89 (02) 197-203
- 8 Mantripragada VP, Piuzzi NS, Zachos T, Obuchowski NA, Muschler GF, Midura RJ. Histopathological assessment of primary osteoarthritic knees in large patient cohort reveal the possibility of several potential patterns of osteoarthritis initiation. Curr Res Transl Med 2017; 65 (04) 133-139
- 9 Cohen SB, Sharkey PF. Subchondroplasty for treating bone marrow lesions. J Knee Surg 2016; 29 (07) 555-563
- 10 Zanetti M, Bruder E, Romero J, Hodler J. Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology 2000; 215 (03) 835-840
- 11 Bonadio MB, Giglio PN, Helito CP, Pécora JR, Camanho GL, Demange MK. Subchondroplasty for treating bone marrow lesions in the knee–initial experience. Rev Bras Ortop (English edition) 2017; 52 (03) 325-330
- 12 Matheny JB, Goff MG, Pownder SL. , et al. An in vivo model of a mechanically-induced bone marrow lesion. J Biomech 2017; 64: 258-261
- 13 Kon E, Ronga M, Filardo G. , et al. Bone marrow lesions and subchondral bone pathology of the knee. Knee Surg Sports Traumatol Arthrosc 2016; 24 (06) 1797-1814
- 14 Tanamas SK, Wluka AE, Pelletier JP. , et al. Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology (Oxford) 2010; 49 (12) 2413-2419
- 15 Roemer FW, Neogi T, Nevitt MC. , et al. Subchondral bone marrow lesions are highly associated with, and predict subchondral bone attrition longitudinally: the MOST study. Osteoarthritis Cartilage 2010; 18 (01) 47-53
- 16 Felson DT, Niu J, Guermazi A. , et al. Correlation of the development of knee pain with enlarging bone marrow lesions on magnetic resonance imaging. Arthritis Rheum 2007; 56 (09) 2986-2992
- 17 Fulkerson JP. Current concepts. Diagnosis and treatment of patients with patellofemoral pain. Am J Sports Med 2002; 30 (03) 447-456
- 18 Scher C, Craig J, Nelson F. Bone marrow edema in the knee in osteoarthrosis and association with total knee arthroplasty within a three-year follow-up. Skeletal Radiol 2008; 37 (07) 609-617
- 19 Mantripragada VP, Bova WA, Boehm C. , et al. Progenitor cells from different zones of human cartilage and their correlation with histopathological osteoarthritis progression. J Orthop Res 2018; 36 (06) 1728-1738
- 20 Li X, Ma BC, Bolbos RI. , et al. Quantitative assessment of bone marrow edema-like lesion and overlying cartilage in knees with osteoarthritis and anterior cruciate ligament tear using MR imaging and spectroscopic imaging at 3 Tesla. J Magn Reson Imaging 2008; 28 (02) 453-461
- 21 Räsänen P, Paavolainen P, Sintonen H. , et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop 2007; 78 (01) 108-115
- 22 Klit J, Jacobsen S, Rosenlund S, Sonne-Holm S, Troelsen A. Total knee arthroplasty in younger patients evaluated by alternative outcome measures. J Arthroplasty 2014; 29 (05) 912-917
- 23 Chahla J, Piuzzi NS, Mitchell JJ. , et al. Intra-articular cellular therapy for osteoarthritis and focal cartilage defects of the knee: a systematic review of the literature and study quality analysis. J Bone Joint Surg Am 2016; 98 (18) 1511-1521
- 24 Howell SM, Shelton TJ, Hull ML. Implant survival and function ten years after kinematically aligned total knee arthroplasty. J Arthroplasty 2018; 33 (12) 3678-3684
- 25 Gathen M, Wimmer MD, Ploeger MM. , et al. Comparison of two-stage revision arthroplasty and intramedullary arthrodesis in patients with failed infected knee arthroplasty. Arch Orthop Trauma Surg 2018; 138 (10) 1443-1452
- 26 Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the medicare population. J Arthroplasty 2018; 33 (10) 3238-3245
- 27 Hernandez NM, Parry JA, Mabry TM, Taunton MJ. Patients at risk: preoperative opioid use affects opioid prescribing, refills, and outcomes after total knee arthroplasty. J Arthroplasty 2018; 33 (7S): S142-S146
- 28 Rutherford RW, Jennings JM, Levy DL, Parisi TJ, Martin JR, Dennis DA. Revision total knee arthroplasty for arthrofibrosis. J Arthroplasty 2018; 33 (7S): S177-S181
- 29 Lespasio MJ, Piuzzi NS, Husni ME, Muschler GF, Guarino A, Mont MA. Knee osteoarthritis: a primer. Perm J 2017 21. Doi: 10.7812/TPP/16-183
- 30 Goh GSH, Bin Abd Razak HR, Tay DKJ, Chia SL, Lo NN, Yeo SJ. Unicompartmental knee arthroplasty achieves greater flexion with no difference in functional outcome, quality of life, and satisfaction vs total knee arthroplasty in patients younger than 55 years. a propensity score-matched cohort analysis. J Arthroplasty 2018; 33 (02) 355-361
- 31 Scott CEH, Oliver WM, MacDonald D, Wade FA, Moran M, Breusch SJ. Predicting dissatisfaction following total knee arthroplasty in patients under 55 years of age. Bone Joint J 2016; 98-B (12) 1625-1634
- 32 Rodriguez-Fontan F, Piuzzi NS, Kraeutler MJ, Pascual-Garrido C. Early clinical outcomes of intra-articular injections of bone marrow aspirate concentrate for the treatment of early osteoarthritis of the hip, and knee: a cohort study. PM R 2018; 10 (12) 1353-1359
- 33 Piuzzi NS, Ng M, Chughtai M. , et al. The stem-cell market for the treatment of knee osteoarthritis: a patient perspective. J Knee Surg 2018; 31 (06) 551-556
- 34 Piuzzi NS, Khlopas A, Sodhi N. , et al. Cellular therapies in orthopedics: where are we?. Surg Technol Int 2017; 31: 359-364
- 35 Piuzzi NS, Chughtai M, Khlopas A. , et al. Platelet-rich plasma for the treatment of knee osteoarthritis: a review. J Knee Surg 2017; 30 (07) 627-633
- 36 Piuzzi NS, Khlopas A, Newman JM. , et al. Bone marrow cellular therapies: novel therapy for knee osteoarthritis. J Knee Surg 2018; 31 (01) 22-26
- 37 Ramkumar PN, Navarro SM, Haeberle HS. , et al. Cellular therapy injections in today's orthopedic market: A social media analysis. Cytotherapy 2017; 19 (12) 1392-1399
- 38 Meheux CJ, McCulloch PC, Lintner DM, Varner KE, Harris JD. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy 2016; 32 (03) 495-505
- 39 Piuzzi NS, Ng M, Kantor A. , et al. What is the price and claimed efficacy of platelet-rich plasma injections for the treatment of knee osteoarthritis in the united states?. J Knee Surg 2018 Doi: 10.1055/s-0038-1669953
- 40 Andia I, Maffulli N. Use of platelet-rich plasma for patellar tendon and medial collateral ligament injuries: best current clinical practice. J Knee Surg 2015; 28 (01) 11-18
- 41 Franklin SP, Stoker AM, Bozynski CC. , et al. Comparison of platelet-rich plasma, stromal vascular fraction (SVF), or SVF with an Injectable PLGA nanofiber scaffold for the treatment of osteochondral injury in dogs. J Knee Surg 2018; 31 (07) 686-697
- 42 Stoker AM, Baumann CA, Stannard JP, Cook JL. Bone marrow aspirate concentrate versus platelet rich plasma to enhance osseous integration potential for osteochondral allografts. J Knee Surg 2018; 31 (04) 314-320
- 43 Birdwhistell KE, Karumbaiah L, Franklin SP. Sustained release of transforming growth factor-β1 from platelet-rich chondroitin sulfate glycosaminoglycan gels. J Knee Surg 2018; 31 (05) 410-415
- 44 Kopka M, Bradley JP. The use of biologic agents in athletes with knee injuries. J Knee Surg 2016; 29 (05) 379-386
- 45 Beitzel K, Allen D, Apostolakos J. , et al. U.S. definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. J Knee Surg 2015; 28 (01) 29-34
- 46 LaPrade CM, James EW, LaPrade RF, Engebretsen L. How should we evaluate outcomes for use of biologics in the knee?. J Knee Surg 2015; 28 (01) 35-44
- 47 Hutchinson ID, Rodeo SA, Perrone GS, Murray MM. Can platelet-rich plasma enhance anterior cruciate ligament and meniscal repair?. J Knee Surg 2015; 28 (01) 19-28
- 48 Mascarenhas R, Saltzman BM, Fortier LA, Cole BJ. Role of platelet-rich plasma in articular cartilage injury and disease. J Knee Surg 2015; 28 (01) 3-10
- 49 M, Delgado D, Sánchez P. , et al. Combination of intra-articular and intraosseous injections of platelet rich plasma for severe knee osteoarthritis: a pilot study. BioMed Res Int 2016; 2016: 4868613
- 50 Sánchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol 2008; 26 (05) 910-913
- 51 Anitua E, Sánchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 2010; 62 (7,8): 741-752
- 52 Richardson D, Pearson RG, Kurian N. , et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008; 10 (02) R43
- 53 Roffi A, Di Matteo B, Krishnakumar GS, Kon E, Filardo G. Platelet-rich plasma for the treatment of bone defects: from pre-clinical rational to evidence in the clinical practice. A systematic review. Int Orthop 2017; 41 (02) 221-237
- 54 Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. Am J Sports Med 2017; 45 (02) 339-346
- 55 Filardo G, Di Matteo B, Di Martino A. , et al. Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. Am J Sports Med 2015; 43 (07) 1575-1582
- 56 Astur DC, de Freitas EV, Cabral PB. , et al. Evaluation and management of subchondral calcium phosphate injection technique to treat bone marrow lesion. Cartilage 2018; 1947603518770249 (e-pub ahead of print) doi: 10.1177/1947603518770249
- 57 Sánchez M, Delgado D, Pompei O. , et al. Treating severe knee osteoarthritis with combination of intra-osseous and intra-articular infiltrations of platelet-rich plasma: an observational study. Cartilage 2018; 1947603518756462 (e-pub ahead of print) doi: 10.1177/1947603518756462
- 58 Su K, Bai Y, Wang J, Zhang H, Liu H, Ma S. Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. Clin Rheumatol 2018; 37 (05) 1341-1350
- 59 Moher D, Liberati A, Tetzlaff J, Altman DG. ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
- 60 Moher D, Shamseer L, Clarke M. , et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4 (01) 1-9
- 61 Harris JD, Quatman CE, Manring MM, Siston RA, Flanigan DC. How to write a systematic review. Am J Sports Med 2014; 42 (11) 2761-2768
- 62 Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. J Bone Joint Surg Am 2003; 85-A (01) 1-3
- 63 Slobogean G, Bhandari M. Introducing levels of evidence to the Journal of Orthopaedic Trauma: implementation and future directions. J Orthop Trauma 2012; 26 (03) 127-128
- 64 Chu CR, Rodeo S, Bhutani N. , et al. Optimizing clinical use of biologics in orthopaedic surgery: consensus recommendations from the 2018 AAOS/NIH U-13 conference. J Am Acad Orthop Surg 2018; 27 (02) e50-e63